GMED Globus Medical
- Official Name: GLOBUS MEDICAL, INC.
- Headquarters: 2560 General Armistead Ave, AUDUBON, PA, 19403 US
- CEO: Daniel Scavilla
- Website: globusmedical.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Lost by 3.126 | (2.471) - 0.655 | ||
| 2025-07-17 | 1 | Won by 2.578 | 1.415 - (1.163) | ||
| 2025-07-24 | 2 | Lost by 6.839 | (2.567) - 4.272 | ||
| 2025-07-31 | 3 | Lost by 1.789 | (1.247) - 0.542 | ||
| 2025-08-07 | 4 | Won by 5.653 | 2.499 - (3.154) | ||
| 2025-08-14 | 5 | Lost by 6.474 | 9.307 - 15.781 | ||
| 2025-08-21 | 6 | Lost by 1.413 | 0.753 - 2.166 | ||
| 2025-08-28 | 7 | Won by 1.829 | 1.145 - (0.684) | ||
| 2025-09-04 | 8 | Won by 3.842 | (1.356) - (5.198) | ||
| 2025-09-11 | 9 | Lost by 4.364 | (1.150) - 3.214 | ||
| 2025-09-18 | 10 | Lost by 16.505 | (5.656) - 10.849 | ||
| 2025-09-25 | 11 | Lost by 1.844 | (2.743) - (0.899) | ||
| 2025-10-02 | 12 | Won by 3.156 | 4.523 - 1.367 | ||
| 2025-10-09 | 13 | Won by 6.574 | 2.453 - (4.121) | ||
| 2025-10-16 | 14 | Won by 1.522 | (1.784) - (3.306) | ||
| 2025-10-23 | 15 | Won by 5.992 | 7.122 - 1.130 |
Latest News

Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosyst...

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industr...

Can This Number Push ISRG Stock Higher?
Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. ...

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.

Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.

Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospe...